metronidazolo baxter o,5%
baxter s.p.a. - metronidazolo - metronidazolo
tioguanina aspen
aspen pharma trading limited - tioguanina - tioguanina
trazer
s.f. group s.r.l. - itraconazolo - itraconazolo
strimvelis
fondazione telethon ets - autologhe cd34 + arricchita frazione di cellule che contiene le cellule cd34 + trasformate con un vettore retrovirale che codifica per la sequenza del cdna umano adenosina deaminasi (ada) da umano cellule staminali/progenitrici (cd34 +) - immunodeficienza grave associata - immunostimolanti, - strimvelis è indicato per il trattamento di pazienti con immunodeficienza combinata grave deficit di adenosina deaminasi (ada-scid), per i quali nessun antigene umano adatto del leucocita (hla)-donatore di cellule staminali correlate abbinato è disponibile (vedere paragrafo 4. 2 e sezione 4.
deflamon
spa societa' prodotti antibiotici s.p.a. - metronidazolo - metronidazolo
flagyl
teofarma s.r.l. - metronidazolo - metronidazolo
metronidazolo kabi
fresenius kabi italia s.r.l. - metronidazolo - metronidazolo
metronidazolo s.a.l.f.
s.a.l.f. spa laboratorio farmacologico - metronidazolo - metronidazolo
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agenti antineoplastici - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
melfalan sun
sun pharmaceutical industries (europe) b.v. - melfalan - melfalan